1. Home
  2. ANGO vs ALT Comparison

ANGO vs ALT Comparison

Compare ANGO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANGO
  • ALT
  • Stock Information
  • Founded
  • ANGO 1988
  • ALT 1997
  • Country
  • ANGO United States
  • ALT United States
  • Employees
  • ANGO N/A
  • ALT N/A
  • Industry
  • ANGO Medical/Dental Instruments
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANGO Health Care
  • ALT Health Care
  • Exchange
  • ANGO Nasdaq
  • ALT Nasdaq
  • Market Cap
  • ANGO 406.9M
  • ALT 472.3M
  • IPO Year
  • ANGO 2004
  • ALT N/A
  • Fundamental
  • Price
  • ANGO $9.78
  • ALT $3.94
  • Analyst Decision
  • ANGO Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • ANGO 2
  • ALT 6
  • Target Price
  • ANGO $14.00
  • ALT $20.20
  • AVG Volume (30 Days)
  • ANGO 712.9K
  • ALT 10.1M
  • Earning Date
  • ANGO 07-15-2025
  • ALT 08-07-2025
  • Dividend Yield
  • ANGO N/A
  • ALT N/A
  • EPS Growth
  • ANGO N/A
  • ALT N/A
  • EPS
  • ANGO N/A
  • ALT N/A
  • Revenue
  • ANGO $283,320,000.00
  • ALT $20,000.00
  • Revenue This Year
  • ANGO N/A
  • ALT N/A
  • Revenue Next Year
  • ANGO $6.35
  • ALT $1,557,547.90
  • P/E Ratio
  • ANGO N/A
  • ALT N/A
  • Revenue Growth
  • ANGO N/A
  • ALT N/A
  • 52 Week Low
  • ANGO $5.47
  • ALT $2.90
  • 52 Week High
  • ANGO $13.50
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • ANGO 42.59
  • ALT 29.83
  • Support Level
  • ANGO $9.75
  • ALT $2.90
  • Resistance Level
  • ANGO $10.24
  • ALT $7.73
  • Average True Range (ATR)
  • ANGO 0.42
  • ALT 0.64
  • MACD
  • ANGO -0.14
  • ALT -0.32
  • Stochastic Oscillator
  • ANGO 6.21
  • ALT 12.42

About ANGO AngioDynamics Inc.

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: